Arrowhead Pharmaceuticals, Inc. Profile Avatar - Palmy Investing

Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for…

Biotechnology
US, Pasadena [HQ]
Financials

Analysts

Earnings
Reported
Past Estimate Consensus
Future Estimate Consensus
EPS Revenue EBITDA EBIT SGA
FY EPS Revenue [mil.] Profit [mil.] EBITDA [mil.] EBIT [mil.] Expenses · SGA [mil.]
E E E E E E
All monetary values are presented in USD ($). E stands for Estimate.
2014 -1.2500 -0.740 0.18 0.24 -58 -50 -41 -49 -51 -52 24 0.11
2015 -1.6000 -1.610 0.38 0.48 -91 -171 -96 0.30 -95 0.31 34 0.22
2016 -1.3400 -1.288 0.16 0.74 -81 -137 -74 0.46 -79 0.48 40 0.33
2017 -0.4700 -0.423 31 30 -34 -45 -33 -19 -36 -19 32 13
2018 -0.6500 -0.088 16 59 -54 -9 -51 -36 -55 -38 19 26
2019 0.7200 0.757 168 165 67 56 65 61 61 47 26 34
2020 -0.8400 -0.254 87 132 -84 -352 -87 -334 -93 -376 52 123
2021 -1.3600 -0.693 138 134 -140 -349 -140 -333 -149 -359 80 60
2022 -1.6700 -1.605 243 1,179 -176 -98 -178 -58 -188 -124 124 433
2023 -1.9200 -1.496 240 263 -205 -296 -188 -101 -217 -166 92 117
2024 - -4.567 - 62 - -538 - -38 - -40 - 27
2025 - -4.362 - 143 - -497 - -89 - -93 - 64
2026 - -3.902 - 234 - 2.F12X/td> - 2.F121/td> - 2.F121 - 2.F121
2027 - -2.440 - 476 - 1.F13X/td> - 1.F131/td> - 1.F131 - 1.F131
2028 - -2.091 - 612 - 0.F14X/td> - 0.F141/td> - 0.F141 - 0.F141
Institutional Sentiment
Morgan Stanley
1Y Ago:
Equal-Weight
Prev. Grade
Equal-Weight
Dec. 1, 2024
Equal-Weight
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Citigroup
1Y Ago:
Equal-Weight
Prev. Grade
Equal-Weight
Dec. 1, 2024
Equal-Weight
Overall Consensus
Grading Consensus
Click to each, to see the grade
Price Target Consensus

-143.136% $27.84 · MISS

Nov. 6, 2024
Price Then
$20.57
Price Target
$47.29
Price Now
$19.45
End of ARWR's Analysis
CIK: 879407 CUSIP: 04280A100 ISIN: US04280A1007 LEI: - UEI: -
Secondary Listings
ARWR has no secondary listings inside our databases.